187 related articles for article (PubMed ID: 31380290)
21. Metabolomics of papillary thyroid carcinoma tissues: potential biomarkers for diagnosis and promising targets for therapy.
Shang X; Zhong X; Tian X
Tumour Biol; 2016 Aug; 37(8):11163-75. PubMed ID: 26935059
[TBL] [Abstract][Full Text] [Related]
22. LC-MS based serum metabonomic analysis for renal cell carcinoma diagnosis, staging, and biomarker discovery.
Lin L; Huang Z; Gao Y; Yan X; Xing J; Hang W
J Proteome Res; 2011 Mar; 10(3):1396-405. PubMed ID: 21186845
[TBL] [Abstract][Full Text] [Related]
23. Integrated transcriptomic and metabolomic analysis shows that disturbances in metabolism of tumor cells contribute to poor survival of RCC patients.
Popławski P; Tohge T; Bogusławska J; Rybicka B; Tański Z; Treviño V; Fernie AR; Piekiełko-Witkowska A
Biochim Biophys Acta Mol Basis Dis; 2017 Mar; 1863(3):744-752. PubMed ID: 28012969
[TBL] [Abstract][Full Text] [Related]
24. Nuclear Magnetic Resonance metabolomics reveals an excretory metabolic signature of renal cell carcinoma.
Monteiro MS; Barros AS; Pinto J; Carvalho M; Pires-Luís AS; Henrique R; Jerónimo C; Bastos ML; Gil AM; Guedes de Pinho P
Sci Rep; 2016 Nov; 6():37275. PubMed ID: 27857216
[TBL] [Abstract][Full Text] [Related]
25. Searching for prognostic biomarkers for small renal masses in the urinary proteome.
Di Meo A; Batruch I; Brown MD; Yang C; Finelli A; Jewett MA; Diamandis EP; Yousef GM
Int J Cancer; 2020 Apr; 146(8):2315-2325. PubMed ID: 31465112
[TBL] [Abstract][Full Text] [Related]
26. LC-MS-Based Urine Metabolomics Analysis for the Diagnosis and Monitoring of Medulloblastoma.
Liu X; Li J; Hao X; Sun H; Zhang Y; Zhang L; Jia L; Tian Y; Sun W
Front Oncol; 2022; 12():949513. PubMed ID: 35936679
[TBL] [Abstract][Full Text] [Related]
27. Urinary metabolomic profiling for noninvasive diagnosis of acute T cell-mediated rejection after kidney transplantation.
Kim SY; Kim BK; Gwon MR; Seong SJ; Ohk B; Kang WY; Lee HW; Jung HY; Cho JH; Chung BH; Lee SH; Kim YH; Yoon YR; Kim CD; Cho S
J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Jun; 1118-1119():157-163. PubMed ID: 31054449
[TBL] [Abstract][Full Text] [Related]
28. MicroRNA-15a expression measured in urine samples as a potential biomarker of renal cell carcinoma.
Mytsyk Y; Dosenko V; Borys Y; Kucher A; Gazdikova K; Busselberg D; Caprnda M; Kruzliak P; Farooqi AA; Lubov M
Int Urol Nephrol; 2018 May; 50(5):851-859. PubMed ID: 29549624
[TBL] [Abstract][Full Text] [Related]
29. Urine aquaporin 1 and perilipin 2 differentiate renal carcinomas from other imaged renal masses and bladder and prostate cancer.
Morrissey JJ; Mobley J; Figenshau RS; Vetter J; Bhayani S; Kharasch ED
Mayo Clin Proc; 2015 Jan; 90(1):35-42. PubMed ID: 25572193
[TBL] [Abstract][Full Text] [Related]
30. Urinary and Plasma Metabolomics Identify the Distinct Metabolic Profile of Disease State in Chronic Mouse Model of Multiple Sclerosis.
Singh J; Cerghet M; Poisson LM; Datta I; Labuzek K; Suhail H; Rattan R; Giri S
J Neuroimmune Pharmacol; 2019 Jun; 14(2):241-250. PubMed ID: 30315511
[TBL] [Abstract][Full Text] [Related]
31. Discovery and validation of potential urinary biomarkers for bladder cancer diagnosis using a pseudotargeted GC-MS metabolomics method.
Zhou Y; Song R; Ma C; Zhou L; Liu X; Yin P; Zhang Z; Sun Y; Xu C; Lu X; Xu G
Oncotarget; 2017 Mar; 8(13):20719-20728. PubMed ID: 28157703
[TBL] [Abstract][Full Text] [Related]
32. Development of urinary pseudotargeted LC-MS-based metabolomics method and its application in hepatocellular carcinoma biomarker discovery.
Shao Y; Zhu B; Zheng R; Zhao X; Yin P; Lu X; Jiao B; Xu G; Yao Z
J Proteome Res; 2015 Feb; 14(2):906-16. PubMed ID: 25483141
[TBL] [Abstract][Full Text] [Related]
33. Identification of key metabolites during cisplatin-induced acute kidney injury using an HPLC-TOF/MS-based non-targeted urine and kidney metabolomics approach in rats.
Qu X; Gao H; Sun J; Tao L; Zhang Y; Zhai J; Song Y; Hu T; Li Z
Toxicology; 2020 Feb; 431():152366. PubMed ID: 31926187
[TBL] [Abstract][Full Text] [Related]
34. Coccidioidomycosis Detection Using Targeted Plasma and Urine Metabolic Profiling.
Jasbi P; Mitchell NM; Shi X; Grys TE; Wei Y; Liu L; Lake DF; Gu H
J Proteome Res; 2019 Jul; 18(7):2791-2802. PubMed ID: 31244214
[TBL] [Abstract][Full Text] [Related]
35. A Unique Urinary Metabolic Feature for the Determination of Bladder Cancer, Prostate Cancer, and Renal Cell Carcinoma.
Lee S; Ku JY; Kang BJ; Kim KH; Ha HK; Kim S
Metabolites; 2021 Sep; 11(9):. PubMed ID: 34564407
[TBL] [Abstract][Full Text] [Related]
36. Urinary Metabolomics Validates Metabolic Differentiation Between Renal Cell Carcinoma Stages and Reveals a Unique Metabolic Profile for Oncocytomas.
Falegan OS; Arnold Egloff SA; Zijlstra A; Hyndman ME; Vogel HJ
Metabolites; 2019 Jul; 9(8):. PubMed ID: 31344778
[TBL] [Abstract][Full Text] [Related]
37. Prediction and diagnosis of renal cell carcinoma using nuclear magnetic resonance-based serum metabolomics and self-organizing maps.
Zheng H; Ji J; Zhao L; Chen M; Shi A; Pan L; Huang Y; Zhang H; Dong B; Gao H
Oncotarget; 2016 Sep; 7(37):59189-59198. PubMed ID: 27463020
[TBL] [Abstract][Full Text] [Related]
38. Development of a universal metabolome-standard method for long-term LC-MS metabolome profiling and its application for bladder cancer urine-metabolite-biomarker discovery.
Peng J; Chen YT; Chen CL; Li L
Anal Chem; 2014 Jul; 86(13):6540-7. PubMed ID: 24877652
[TBL] [Abstract][Full Text] [Related]
39. Investigation of Plasma Metabolic and Lipidomic Characteristics of a Chinese Cohort and a Pilot Study of Renal Cell Carcinoma Biomarker.
Liu X; Zhang M; Liu X; Sun H; Guo Z; Tang X; Wang Z; Li J; He L; Zhang W; Wang Y; Li H; Fan L; Tsang SX; Zhang Y; Sun W
Front Oncol; 2020; 10():1507. PubMed ID: 33014794
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
